Shares of Aileron Therapeutics Inc (NASDAQ:ALRN) have received an average broker rating score of 1.00 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy recommendation.

Analysts have set a twelve-month consensus price objective of $19.33 for the company, according to Zacks. Zacks has also given Aileron Therapeutics an industry rank of 108 out of 265 based on the ratings given to its competitors.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jennison Associates LLC acquired a new stake in shares of Aileron Therapeutics in the 2nd quarter worth about $2,788,000. Goldman Sachs Group Inc. acquired a new stake in shares of Aileron Therapeutics in the 2nd quarter worth about $418,000. Sphera Funds Management LTD. acquired a new stake in shares of Aileron Therapeutics in the 2nd quarter worth about $1,394,000. Neuberger Berman Group LLC acquired a new stake in shares of Aileron Therapeutics in the 2nd quarter worth about $279,000. Finally, Nexthera Capital LP acquired a new stake in shares of Aileron Therapeutics in the 2nd quarter worth about $1,272,000. Institutional investors own 7.64% of the company’s stock.

Aileron Therapeutics (ALRN) opened at $9.87 on Wednesday. Aileron Therapeutics has a fifty-two week low of $9.58 and a fifty-two week high of $15.48.

ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/13/analysts-set-19-33-price-target-for-aileron-therapeutics-inc-alrn.html.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.

Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.